This finding is somewhat paradoxical because the genetic differences that define IDH-mutant glioma subtypes are prognostic [1], predictive of response to chemotherapy [4, 5], and correlate with distinct tumor microenvironments [2, 6]. Here, IDH1 is linked to central nervous system cancer.